대사 패널 검사 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 분석물별, 질환별, 최종 용도별, 지역별, 경쟁별(2020-2030년)

The Global Metabolic Panel Testing Market was valued at USD 12.41 billion in 2024 and is projected to reach USD 21.56 billion by 2030, growing at a CAGR of 9.62% during the forecast period. The market is expanding steadily as healthcare systems globally prioritize early diagnosis and preventive healthcare. Comprehensive Metabolic Panel (CMP) testing has become a routine diagnostic tool, offering insights into kidney and liver function, blood glucose, and electrolyte balance. The increasing prevalence of metabolic disorders such as diabetes, kidney disease, and liver dysfunction has made CMP tests vital in clinical diagnostics. Additionally, an aging population and the rising importance of routine health monitoring are enlarging the patient base for these tests. CMP testing is now a regular part of wellness checkups in both inpatient and outpatient settings. Technological advancements, including laboratory automation and digital data integration, are enhancing testing efficiency and accuracy. The rising popularity of personalized medicine and point-of-care testing devices, particularly in urgent care and remote areas, is making these diagnostics more accessible and contributing to overall market growth.

Key Market Drivers

Rising Prevalence of Chronic and Metabolic Disorders

The growing incidence of chronic and metabolic disorders is a major driver of the Global Metabolic Panel Testing Market. Noncommunicable diseases (NCDs) such as cardiovascular conditions, cancer, chronic respiratory diseases, and diabetes are now the leading causes of mortality globally. In 2021, NCDs were responsible for 75% of all deaths worldwide, with cardiovascular diseases causing 19 million deaths, cancers 10 million, chronic respiratory diseases 4 million, and diabetes over 2 million. Metabolic disorders like hypertension, high blood sugar, and elevated lipid levels are critical risk factors for these conditions. A global meta-analysis involving 28 million individuals found that the prevalence of metabolic syndrome ranges from 12.5% to 31.4%, with higher rates in the Eastern Mediterranean and the Americas. Many of these conditions remain undiagnosed until complications arise, highlighting the need for regular metabolic screening through CMP tests for early detection and preventive intervention.

Key Market Challenges

High Cost of Advanced Diagnostic Equipment

The cost associated with acquiring and operating advanced diagnostic equipment remains a key challenge in the Global Metabolic Panel Testing Market. Accurate CMP testing relies on sophisticated analyzers capable of evaluating multiple biomarkers, including glucose levels, enzymes, and electrolytes. These instruments involve substantial capital investment and require ongoing expenditure on maintenance and consumables. For smaller or resource-limited healthcare facilities, especially in developing regions, such expenses can be prohibitive. Smaller diagnostic laboratories may be unable to justify or afford the cost, leading to limited test offerings or dependence on outdated systems with lower accuracy and efficiency. This creates disparities in access to reliable diagnostics across different regions and facility types, posing a challenge to universal healthcare goals.

Key Market Trends

Shift Toward Personalized and Preventive Healthcare

A prominent trend influencing the Global Metabolic Panel Testing Market is the transition toward personalized and preventive healthcare. As healthcare providers increasingly focus on early detection and tailored treatment strategies, CMP testing plays an essential role in identifying metabolic imbalances before clinical symptoms emerge. The ability to detect early signs of conditions such as diabetes and hypertension allows for customized treatment planning, enhancing patient care outcomes. Advances in genomics are further supporting this shift, as genetic profiling is combined with CMP results to develop individualized health management approaches. This integration is fostering a proactive model of care, with the emphasis shifting from disease treatment to early intervention and disease prevention.

Key Market Players

• Abbott Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings Limited
• Sonic Healthcare Limited
• Unipath Specialty Laboratory Limited
• SYNLAB International GmbH
• ARUP Laboratories
• Genoptix, Inc.
• Nova Medical, Inc.
• Mindray Medical International Limited

Report Scope:

In this report, the Global Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Panel Testing Market, By Analytes:

• K+
• Na+
• Cl-
• CO2
• Glucose
• BUN
• Creatinine
• Ca++
• Albumin
• Total protein
• ALP
• ALT
• AST
• Total bilirubin

Metabolic Panel Testing Market, By Disease:

• Kidney Disease
• Liver Disease
• Diabetes
• Others

Metabolic Panel Testing Market, By End Use:

• Laboratory
• PoC
• PoC (Instruments)

Metabolic Panel Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Panel Testing Market.

Available Customizations:

Global Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Metabolic Panel Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
  • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
  • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Metabolic Panel Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Analytes
  • 6.2.2. By Disease
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolic Panel Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Analytes
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Metabolic Panel Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Analytes
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Metabolic Panel Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Analytes
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End Use

7. Europe Metabolic Panel Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Analytes
  • 7.2.2. By Disease
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Metabolic Panel Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Analytes
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Metabolic Panel Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Analytes
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Metabolic Panel Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Analytes
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Metabolic Panel Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Analytes
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Metabolic Panel Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Analytes
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Metabolic Panel Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Analytes
  • 8.2.2. By Disease
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolic Panel Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Analytes
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Metabolic Panel Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Analytes
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Metabolic Panel Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Analytes
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Metabolic Panel Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Analytes
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Metabolic Panel Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Analytes
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End Use

9. South America Metabolic Panel Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Analytes
  • 9.2.2. By Disease
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolic Panel Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Analytes
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Metabolic Panel Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Analytes
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Metabolic Panel Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Analytes
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Metabolic Panel Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Analytes
  • 10.2.2. By Disease
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolic Panel Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Analytes
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Metabolic Panel Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Analytes
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Metabolic Panel Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Analytes
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Quest Diagnostics Incorporated
• 14.3. Laboratory Corporation of America Holdings Limited
• 14.4. Sonic Healthcare Limited
• 14.5. Unipath Specialty Laboratory Limited
• 14.6. SYNLAB International GmbH
• 14.7. ARUP Laboratories
• 14.8. Genoptix, Inc.
• 14.9. Nova Medical, Inc.
• 14.10. Mindray Medical International Limited

15. Strategic Recommendations

16. About Us & Disclaimer